|
Marinus Pharmaceuticals, Inc.
Ticker Symbol: MRNS* CUSIP: 56854Q200 Previous CUSIP: 56854Q101 Exchange: NGM
* NOTE: This security is no longer trading as of 2/11/2025
Company's Online Profile
BUSINESS: Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
|
Notes: September 22, 2020 -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today. Beginning with the opening of trading on September 23, 2020, the Company’s common stock will trade on The Nasdaq Global Market on a split-adjusted basis under a new CUSIP number 56854Q200.
|
IPO - 7/31/2014 - 5.63 Million Shares @ $8.00 /share.
Link to IPO Prospectus
Small Cap Stock -
Market Value $ Million
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Address and Phone Numbers |
| Address: 5 Radnor Corporate Center, Suite 500, 100 Matsonford Rd, Radnor, PA 19087 |
| Main Phone Number |
484-801-4670 |
| Fax Number |
Not Available |
| Investor Relations
Sasha Damouni Ellis
|
484-253-6792
|
| CEO - Scott Braunstein |
CFO -
Steven E. Pfanstiel |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
